Company intelligence / Profile preview
HealVax
Freienbach, Schwyz, Switzerlandhealvax.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
HealVax is a private Swiss biotech company developing therapeutic vaccines for chronic inflammatory skin disease and related immune-mediated disorders. The company’s lead program is a psoriasis vaccine designed to induce active immunization against interleukin-17, a clinically validated cytokine target in dermatology. HealVax’s platform uses engineered plant virus-derived virus-like particles with an incorporated tetanus-toxoid T cell epitope to enhance immune responses. The company has described additional interest in atopic dermatitis and multiple sclerosis, and has operated with a lean, virtual model supported by academic and biotech collaborations.
- Therapeutic areas
- NeurologyDermatology
- Modalities
- Vaccine
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Saiba GmbH
Beyond the preview
Go deeper on HealVax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HealVax.